Key Points
June 23 (Reuters) - The U.S. Food and Drug Administration has approved Pfizer Inc's (PFE.N) drug to treat hair loss caused by an autoimmune disease, the company said on Friday...
The drug, branded as Litfulo, has been approved for people aged 12 years and older suffering from severe alopecia areata (AA), a condition where the immune system attacks hair follicles and causes hair to fall out, often in clumps...
The FDA's decision makes Litfulo the first to be allowed for the treatment of the condition in adolescents...
"AA affects people of all ages, and not uncommonly, it affects adolescent and younger population, so to have an approved agent for adolescent is a significant leap forward," said Brett King, associate professor of dermatology at Yale School of Medicine, ahead of the decision...
Pfizer's application to the FDA was based on data from a mid- to late-stage study that showed 80% or more hair coverage after six months of using the drug compared to a placebo...
